Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Anika Therapeutics (ANIK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 670,219
  • Shares Outstanding, K 14,640
  • Annual Sales, $ 103,380 K
  • Annual Income, $ 32,550 K
  • 36-Month Beta 1.68
  • Price/Sales 6.35
  • Price/Cash Flow 18.08
  • Price/Book 2.94

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.17 +9.33%
on 03/29/17
46.27 -0.36%
on 04/28/17
+3.54 (+8.33%)
since 03/28/17
3-Month
41.64 +10.72%
on 03/28/17
52.39 -12.00%
on 02/15/17
-4.03 (-8.03%)
since 01/27/17
52-Week
41.38 +11.42%
on 11/03/16
54.96 -16.11%
on 07/05/16
-0.83 (-1.76%)
since 04/28/16

Most Recent Stories

More News
Implied Volatility Surging for Anika Therapeutics (ANIK) Stock Options

Options traders are pricing in a big move for Anika Therapeutics (ANIK) shares as it has huge implied volatility.

ANIK : 46.10 (+0.70%)
Anika to Present at the 2017 Canaccord Genuity Musculoskeletal Conference on March 14, 2017

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology,...

ANIK : 46.10 (+0.70%)
Anika Therapeutics, Inc., (Nasdaq: ANIK) to Ring The Nasdaq Stock Market Opening Bell

What:

ANIK : 46.10 (+0.70%)
NDAQ : 68.64 (-0.04%)
Anika Reports Fourth Quarter and Full Year 2016 Financial Results

--Product Revenue Grows 17% for Full Year of 2016

ANIK : 46.10 (+0.70%)
Novo Nordisk (NVO) Misses Q4 Earnings, Revenues Down Y/Y

Novo Nordisk A/S (NVO) reported fourth-quarter 2016 earnings of 50 cents per American Depository Receipt (ADR), missing the Zacks Consensus Estimate of 52 cents by 3.8%.

ENZ : 8.78 (+0.46%)
ANIK : 46.10 (+0.70%)
SNSS : 3.74 (+0.81%)
AstraZeneca (AZN) Beats on Q4 Earnings but Misses on Sales

AstraZeneca PLC (AZN) reported fourth-quarter 2016 core earnings of $1.21 per American Depositary Share, which comfortably beat the Zacks Consensus Estimate of 51 cents. Core earnings also rose 9% year...

ENZ : 8.78 (+0.46%)
ANIK : 46.10 (+0.70%)
AZN : 30.47 (-1.26%)
LLY : 81.96 (+0.77%)
AMAG Down Despite Positive Data on Makena Auto-Injector

AMAG Pharmaceuticals (AMAG) announced positive top-line results from its pharmacokinetic (PK) study on Makena, subcutaneous auto-injector.

ANIK : 46.10 (+0.70%)
SCMP : 10.32 (+2.18%)
ATRS : 3.19 (+1.59%)
AMAG : 24.40 (-0.81%)
BioMarin's Hemophilia Candidate Included in PRIME Initiative

BioMarin Pharmaceutical Inc. (BMRN) announced that BMN 270, being evaluated for the treatment for severe hemophilia A, has been granted access to Priority Medicines (PRIME), a regulatory initiative by...

ENZ : 8.78 (+0.46%)
ANIK : 46.10 (+0.70%)
BMRN : 95.35 (-0.95%)
SNSS : 3.74 (+0.81%)
Novartis (NVS) Votubia Gets EU Approval for Label Expansion

Novartis (NVS) wins EU approval for label expansion of Votubia in refractory partial-onset seizures in patients with tuberous sclerosis complex.

ANIK : 46.10 (+0.70%)
SCMP : 10.32 (+2.18%)
NVS : 76.91 (-0.19%)
SNSS : 3.74 (+0.81%)
Catabasis Hits 52-Week Low on Poor DMD Drug Study Data

Catabasis (CATB) announced disappointing top-line safety and efficacy data from part B of the MoveDMD study (phase I/II) on edasalonexent (CAT-1004).

ANIK : 46.10 (+0.70%)
CATB : 1.40 (-2.10%)
SCMP : 10.32 (+2.18%)
SRPT : 36.62 (+5.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products and devices that promote the repair, protection and healing of bone, cartilage and soft tissue. These products are based on hyaluronic acid, a naturally-occurring, biocompatible polymer found in the body. Due to...

See More

Support & Resistance

2nd Resistance Point 46.50
1st Resistance Point 46.14
Last Price 46.10
1st Support Level 45.09
2nd Support Level 44.40

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.